BACKGROUND: Betablockade has been shown to have cardioprotective effects in patients under perioperative stress. Besides animal model of septic shock and a small cohort of septic patients, these benefits have not been studied in septic shock patients who require norepinephrine administration. METHODS: After correction of preload, an esmolol bolus (0.2-0.5 mg/kg) followed by continuous 24 h infusion was administered in septic patients with sinus or supraventricular tachycardia (HR > 120/min). Exclusion criteria were severe LV systolic dysfunction, atrioventricular blockade and norepinephrine infusion at rates over 0.5 mg/kg/min. Monitoring with echocardiography and pulmonary artery catheter before, at 2, 6, 12, 24 h following the start and 6 h after ceasing of the esmolol drip. Patients were maintained normovolemic throughout the study and adjustments of concomitant norepinephrine infusion rates were made as required. RESULTS: Ten septic patients (mean age 54.4 ± 18.7), APACHE II 21.5 ± 6.2, CRP 275 ± 78 mg/l, procalcitonin 14.5 ± 10.1 mg/l, were given esmolol drip of 212.5 ± 63.5 mg/h at start to 272.5 ± 89.5 mg/h at 24 h. Heart rate decreased from mean 142 ± 11/min to 112 ± 9/min (p < 0.001) with parallel insignificant reduction of cardiac index (4.94 ± 0.76 to 4.35 ± 0.72 l/min/m(2)). Stroke volume insignificantly increased from 67.1 ± 16.3 ml to 72.9 ± 15.3 ml. No parallel change of pulmonary artery wedge pressure was observed (15.9 ± 3.2 to 15.0 ± 2.4 mmHg) as well as no significant changes of norepinephrine infusion (0.13 ± 0.17 to 0.17 ± 0.19 mg/kg/min), DO(2), VO(2), OER or arterial lactate. CONCLUSIONS: Saving the heart 30 beats/min did not demonstrate adverse impact on global haemodynamics in rates above 110/min. Using well titratable betablocker seems to be safe and cardioprotective in septic shock patients with high cardiac output.
BACKGROUND:Betablockade has been shown to have cardioprotective effects in patients under perioperative stress. Besides animal model of septic shock and a small cohort of septic patients, these benefits have not been studied in septic shockpatients who require norepinephrine administration. METHODS: After correction of preload, an esmolol bolus (0.2-0.5 mg/kg) followed by continuous 24 h infusion was administered in septic patients with sinus or supraventricular tachycardia (HR > 120/min). Exclusion criteria were severe LV systolic dysfunction, atrioventricular blockade and norepinephrine infusion at rates over 0.5 mg/kg/min. Monitoring with echocardiography and pulmonary artery catheter before, at 2, 6, 12, 24 h following the start and 6 h after ceasing of the esmolol drip. Patients were maintained normovolemic throughout the study and adjustments of concomitant norepinephrine infusion rates were made as required. RESULTS: Ten septic patients (mean age 54.4 ± 18.7), APACHE II 21.5 ± 6.2, CRP 275 ± 78 mg/l, procalcitonin 14.5 ± 10.1 mg/l, were given esmolol drip of 212.5 ± 63.5 mg/h at start to 272.5 ± 89.5 mg/h at 24 h. Heart rate decreased from mean 142 ± 11/min to 112 ± 9/min (p < 0.001) with parallel insignificant reduction of cardiac index (4.94 ± 0.76 to 4.35 ± 0.72 l/min/m(2)). Stroke volume insignificantly increased from 67.1 ± 16.3 ml to 72.9 ± 15.3 ml. No parallel change of pulmonary artery wedge pressure was observed (15.9 ± 3.2 to 15.0 ± 2.4 mmHg) as well as no significant changes of norepinephrine infusion (0.13 ± 0.17 to 0.17 ± 0.19 mg/kg/min), DO(2), VO(2), OER or arterial lactate. CONCLUSIONS: Saving the heart 30 beats/min did not demonstrate adverse impact on global haemodynamics in rates above 110/min. Using well titratable betablocker seems to be safe and cardioprotective in septic shockpatients with high cardiac output.
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Hendrik Schmidt; Ursula Müller-Werdan; Thomas Hoffmann; Darrel P Francis; Massimo F Piepoli; Mathias Rauchhaus; Roland Prondzinsky; Harald Loppnow; Michael Buerke; Dirk Hoyer; Karl Werdan Journal: Crit Care Med Date: 2005-09 Impact factor: 7.598
Authors: Gareth L Ackland; Song T Yao; Alain Rudiger; Alex Dyson; Ray Stidwill; Dmitry Poputnikov; Mervyn Singer; Alexander V Gourine Journal: Crit Care Med Date: 2010-02 Impact factor: 7.598
Authors: Jacques Albanèse; Marc Leone; Franck Garnier; Aurélie Bourgoin; François Antonini; Claude Martin Journal: Chest Date: 2004-08 Impact factor: 9.410
Authors: Martin Balik; Jan Rulisek; Pavel Leden; Michal Zakharchenko; Michal Otahal; Hana Bartakova; Josef Korinek Journal: Wien Klin Wochenschr Date: 2013-12-17 Impact factor: 1.704
Authors: Kathleen E Singer; Courtney E Collins; Julie M Flahive; Allison S Wyman; M Didem Ayturk; Heena P Santry Journal: Am J Surg Date: 2017-06-24 Impact factor: 2.565
Authors: Mohamed Ghalayini; Pierre-Yves Brun; Pascal Augustin; Elise Guivarch; Marie Pierre Dilly; Sophie Provenchere; Pierre Mordant; Yves Castier; Philippe Montravers; Dan Longrois Journal: J Extra Corpor Technol Date: 2016-09
Authors: Sarah J Beesley; Emily L Wilson; Michael J Lanspa; Colin K Grissom; Sajid Shahul; Daniel Talmor; Samuel M Brown Journal: Crit Care Med Date: 2017-02 Impact factor: 7.598